Decision to deploy Ervebo vaccine against Bundibugyo Ebola outbreak
The authorities in the Democratic Republic of Congo (DRC) are trialing the Ervebo vaccine to respond to the Bundibugyo Ebola outbreak in the country's northeastern region. While Ervebo is approved for the Zaire Ebola virus strain, no specific vaccine exists for the rapidly spreading Bundibugyo strain within the community.
The current outbreak has resulted in approximately 2,500 deaths, with the number of confirmed cases doubling every 20 days. Health experts warn that without timely intervention, this could become the largest Ebola pandemic in history.
Hope from Ervebo vaccine and its limitations
Although the Ervebo vaccine has not been fully proven effective against the Bundibugyo strain, preliminary laboratory and animal studies suggest it may offer partial protection. Out of the 70,000 vaccine doses provided by the World Health Organization (WHO), a portion will be reserved for phase 3 clinical trials to assess the vaccine's impact on this new strain.



